Standard BioTools Inc
FLB
Company Profile
Business description
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
Contact
2 Tower Place
Suite 2000
South San FranciscoCA94080
USAT: +1 650 266-6000
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
818
Stocks News & Analysis
stocks
Strong results from cheap ASX share
The market responded favourably to results but shares still underpriced.
stocks
Anthropic’s Claude code security release is not bad news for cyber stocks
We believe cyber vendors will be able to adopt LLM’s for their benefit.
stocks
Earnings losers: TWE, GMG, SUN and more fall on weaker profits
Where companies fell short of market expectations in the third week of earnings.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,230.30 | 30.50 | -0.33% |
| CAC 40 | 8,497.17 | 18.32 | -0.22% |
| DAX 40 | 24,991.97 | 268.72 | -1.06% |
| Dow JONES (US) | 48,804.06 | 821.91 | -1.66% |
| FTSE 100 | 10,684.74 | 2.15 | -0.02% |
| HKSE | 26,623.48 | 458.43 | -1.69% |
| NASDAQ | 22,627.27 | 258.79 | -1.13% |
| Nikkei 225 | 57,256.55 | 430.85 | 0.76% |
| NZX 50 Index | 13,504.53 | 84.10 | 0.63% |
| S&P 500 | 6,837.75 | 71.76 | -1.04% |
| S&P/ASX 200 | 9,008.30 | 26.10 | -0.29% |
| SSE Composite Index | 4,124.15 | 42.08 | 1.03% |